NZ220260A - Synergistic combination of t-pa and sod and pharmaceutical formulation - Google Patents

Synergistic combination of t-pa and sod and pharmaceutical formulation

Info

Publication number
NZ220260A
NZ220260A NZ220260A NZ22026087A NZ220260A NZ 220260 A NZ220260 A NZ 220260A NZ 220260 A NZ220260 A NZ 220260A NZ 22026087 A NZ22026087 A NZ 22026087A NZ 220260 A NZ220260 A NZ 220260A
Authority
NZ
New Zealand
Prior art keywords
sod
tissue
pharmaceutical formulation
synergistic combination
medicament
Prior art date
Application number
NZ220260A
Other languages
English (en)
Inventor
Henry Berger
Crist John Frangakis
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US06/862,057 external-priority patent/US4976959A/en
Application filed by Wellcome Found filed Critical Wellcome Found
Publication of NZ220260A publication Critical patent/NZ220260A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/446—Superoxide dismutase (1.15)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21068—Tissue plasminogen activator (3.4.21.68), i.e. tPA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ220260A 1986-05-12 1987-05-11 Synergistic combination of t-pa and sod and pharmaceutical formulation NZ220260A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86204686A 1986-05-12 1986-05-12
US06/862,057 US4976959A (en) 1986-05-12 1986-05-12 T-PA and SOD in limiting tissue damage

Publications (1)

Publication Number Publication Date
NZ220260A true NZ220260A (en) 1990-07-26

Family

ID=27127662

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ220260A NZ220260A (en) 1986-05-12 1987-05-11 Synergistic combination of t-pa and sod and pharmaceutical formulation

Country Status (13)

Country Link
JP (1) JPH0680015B2 (de)
AU (1) AU600724B2 (de)
BE (1) BE1001425A4 (de)
CH (1) CH672989A5 (de)
DE (1) DE3715662A1 (de)
DK (1) DK237187A (de)
FR (1) FR2600895B1 (de)
GB (1) GB2194886B (de)
IE (1) IE59895B1 (de)
LU (1) LU86875A1 (de)
NL (1) NL8701113A (de)
NZ (1) NZ220260A (de)
SE (1) SE8701921L (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0780784B2 (ja) * 1987-10-23 1995-08-30 宇部興産株式会社 微小循環障害に基づく心筋虚血傷害治療薬
NZ230808A (en) * 1988-10-24 1993-04-28 Squibb & Sons Inc Pharmaceutical compositions and combinations containing an angiotensin-converting enzyme inhibitor and a thrombolytic agent
DE4038563A1 (de) * 1990-12-04 1992-06-11 Gruenenthal Gmbh Verwendung von superoxiddismutasen zur prophylaxe und/oder behandlung von organversagen bei risikopatienten mit polytrauma
DE19518625C2 (de) * 1995-05-24 1997-08-07 Buescher Pebueso Beton Verfahren zum Abdichten von Betonrohren und ein für die Durchführung des Verfahrens geeignetes Betonrohr
US6921751B1 (en) 1998-05-20 2005-07-26 Erasmus Universiteit Rotterdam Immunoregulator
US7175679B2 (en) 2001-03-29 2007-02-13 Biotempt B.V. Oligopeptide treatment of NF-κB mediated inflammation
US8680059B2 (en) 1998-05-20 2014-03-25 Biotempt B.V. Oligopeptide acetate and formulations thereof
US20030220258A1 (en) 2001-12-21 2003-11-27 Robbert Benner Treatment of ischemic events
EP1138692A1 (de) 2000-03-29 2001-10-04 Erasmus Universiteit Rotterdam Fragmente des menschlichen Choriongonadotropins als Immunoregulatoren
US6844315B2 (en) 1998-05-20 2005-01-18 Erasmus Universiteit Rotterdam Immunoregulator
EP1300418A1 (de) 2001-10-04 2003-04-09 Erasmus Universiteit Rotterdam Genregulation durch Oligopeptide
USRE43279E1 (en) 2000-03-29 2012-03-27 Biotemp B.V. Compositions capable of reducing elevated blood urea concentration
US7358330B2 (en) 2001-03-29 2008-04-15 Biotempt B.V. Immunoregulatory compositions
US7576174B2 (en) 2000-03-29 2009-08-18 Biotempt B.V. Compositions capable of reducing elevated blood urea concentration
US7786084B2 (en) 2001-12-21 2010-08-31 Biotempt B.V. Treatment of burns
US7501391B2 (en) 2001-12-21 2009-03-10 Biotempt B.V. Treatment of transplant survival
US7517529B2 (en) 2003-04-08 2009-04-14 Biotempt B.V. Treatment of type I diabetes
WO2007004869A2 (en) 2005-07-05 2007-01-11 Biotempt B.V. Treatment of tumors
EP1864692A1 (de) 2006-06-07 2007-12-12 Biotempt B.V. Verwendung von peptiden zum Schutz von Strahlenschäden
US8652476B2 (en) 2009-07-27 2014-02-18 Niigata University Pharmaceutical composition for treating ischemic events
WO2011013668A1 (ja) * 2009-07-27 2011-02-03 国立大学法人新潟大学 虚血性イベントの治療用医薬品組成物
US10617756B2 (en) 2017-01-05 2020-04-14 Shimojani, LLC Drug regimen for treatment of cerebral ischemia

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8003402A (nl) * 1980-06-11 1982-01-04 Leuven Res & Dev Vzw Nieuwe plasminogeen-activator en farmaceutisch preparaat met trombolytische werking.
DE3382389D1 (de) * 1982-12-14 1991-10-02 South African Inventions Plasminogenaktivator.
JPS59196824A (ja) * 1983-04-21 1984-11-08 Kowa Co 吸着防止剤
AT391812B (de) * 1985-05-28 1990-12-10 Wellcome Found Verfahren zur herstellung einer parenteralen t-pa-loesung
US4929444A (en) * 1985-05-28 1990-05-29 Burroughs Wellcome Co. Low pH pharmaceutical formulation containing t-PA
WO1987006831A1 (en) * 1986-05-15 1987-11-19 Emory University Composition and method for treating a thrombus and embolus

Also Published As

Publication number Publication date
IE871210L (en) 1987-11-12
DK237187D0 (da) 1987-05-11
BE1001425A4 (fr) 1989-10-31
GB8711058D0 (en) 1987-06-17
DE3715662A1 (de) 1987-11-19
NL8701113A (nl) 1987-12-01
AU600724B2 (en) 1990-08-23
LU86875A1 (fr) 1988-01-20
SE8701921L (sv) 1987-11-13
FR2600895A1 (fr) 1988-01-08
JPH0680015B2 (ja) 1994-10-12
SE8701921D0 (sv) 1987-05-11
CH672989A5 (de) 1990-01-31
GB2194886B (en) 1990-04-25
GB2194886A (en) 1988-03-23
FR2600895B1 (fr) 1993-12-24
AU7270487A (en) 1987-11-19
IE59895B1 (en) 1994-04-20
JPS6322026A (ja) 1988-01-29
DK237187A (da) 1987-11-13

Similar Documents

Publication Publication Date Title
NZ220260A (en) Synergistic combination of t-pa and sod and pharmaceutical formulation
TW250435B (de)
ZA897173B (en) Pharmaceutically active combination
MX9504415A (es) Eteres antivirales de isoesteres de sustrato de proteasa de aspartato.
GR3034237T3 (en) Process to prepare a cetrorelix lyophilised composition.
MY164077A (en) Compositions and uses of et743 for treating cancer
EP0199117A3 (de) Therapeutische Verwendung von Phosphokreatin
IL163091A (en) Medical product and pharmaceutical composition comprising as active ingredients a thrombolytic agent and levosimendan or a pharmaceutically acceptable salt thereof and the use of same in the manufacture of medicament for reducing mortality of patients with acute myocardial infarction
EP0285906A3 (en) Active agent for combating tumours
NZ218231A (en) Composition containing synergistic combination of plasminogen activator and urokinase activator
AU6997287A (en) The application of tissue plasminogen activator and oxypurinol in dissolving blood clots and in preventing damage to ischaemic tissue during reperfusion
UA885A1 (uk) Засiб для лiкуваhhя шлуhково-кишкових захворюваhь з озhаками дiареї
IT1206281B (it) Attivatore del plasminogeno dei tessuti e suo impiego nella medicina umana ed in veterinaria
MX9710126A (es) Compuestos sustituidos con sulfonamida, procedimiento para su preparacion, su empleo como medicamento o agente de diagnostico, asi como preparados farmaceuticos que los contienen.
GEP19991539B (en) Use of Peptides with Organoprotective Activity
HUT34871A (en) Fungicid preparations of synergetic effect containing several agents